Green Cross - Asset Resilience Ratio
Green Cross (005250) has an Asset Resilience Ratio of 0.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 005250 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Green Cross's Asset Resilience Ratio has changed over time. See 005250 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Green Cross's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Green Cross (005250) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩22.22 Billion | 0.52% |
| Total Liquid Assets | ₩22.22 Billion | 0.52% |
Asset Resilience Insights
- Limited Liquidity: Green Cross maintains only 0.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Green Cross Industry Peers by Asset Resilience Ratio
Compare Green Cross's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Green Cross (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Green Cross.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.19% | ₩6.79 Billion ≈ $4.60 Million |
₩3.67 Trillion ≈ $2.49 Billion |
-0.39pp |
| 2023-12-31 | 0.58% | ₩21.57 Billion ≈ $14.62 Million |
₩3.74 Trillion ≈ $2.53 Billion |
-0.30pp |
| 2022-12-31 | 0.87% | ₩31.34 Billion ≈ $21.24 Million |
₩3.59 Trillion ≈ $2.43 Billion |
-0.92pp |
| 2021-12-31 | 1.80% | ₩62.83 Billion ≈ $42.58 Million |
₩3.50 Trillion ≈ $2.37 Billion |
-0.13pp |
| 2020-12-31 | 1.92% | ₩62.35 Billion ≈ $42.25 Million |
₩3.24 Trillion ≈ $2.20 Billion |
+0.28pp |
| 2019-12-31 | 1.64% | ₩45.49 Billion ≈ $30.82 Million |
₩2.77 Trillion ≈ $1.88 Billion |
+0.86pp |
| 2018-12-31 | 0.78% | ₩20.53 Billion ≈ $13.91 Million |
₩2.63 Trillion ≈ $1.78 Billion |
+0.66pp |
| 2017-12-31 | 0.12% | ₩3.07 Billion ≈ $2.08 Million |
₩2.56 Trillion ≈ $1.74 Billion |
-3.81pp |
| 2016-12-31 | 3.93% | ₩88.35 Billion ≈ $59.87 Million |
₩2.25 Trillion ≈ $1.52 Billion |
+0.30pp |
| 2015-12-31 | 3.63% | ₩74.66 Billion ≈ $50.59 Million |
₩2.06 Trillion ≈ $1.40 Billion |
-0.28pp |
| 2014-12-31 | 3.90% | ₩69.89 Billion ≈ $47.37 Million |
₩1.79 Trillion ≈ $1.21 Billion |
+1.72pp |
| 2013-12-31 | 2.19% | ₩35.51 Billion ≈ $24.06 Million |
₩1.62 Trillion ≈ $1.10 Billion |
+1.16pp |
| 2012-12-31 | 1.02% | ₩14.81 Billion ≈ $10.03 Million |
₩1.45 Trillion ≈ $980.16 Million |
-0.42pp |
| 2011-12-31 | 1.45% | ₩66.57 Billion ≈ $45.12 Million |
₩4.60 Trillion ≈ $3.12 Billion |
-40.76pp |
| 2010-12-31 | 42.21% | ₩1.74 Trillion ≈ $1.18 Billion |
₩4.11 Trillion ≈ $2.79 Billion |
-0.61pp |
| 2009-12-31 | 42.81% | ₩1.43 Trillion ≈ $970.73 Million |
₩3.35 Trillion ≈ $2.27 Billion |
+27.25pp |
| 2008-12-31 | 15.57% | ₩433.26 Billion ≈ $293.61 Million |
₩2.78 Trillion ≈ $1.89 Billion |
+2.25pp |
| 2007-12-31 | 13.31% | ₩323.75 Billion ≈ $219.40 Million |
₩2.43 Trillion ≈ $1.65 Billion |
-5.38pp |
| 2006-12-31 | 18.69% | ₩376.09 Billion ≈ $254.87 Million |
₩2.01 Trillion ≈ $1.36 Billion |
+2.44pp |
| 2005-12-31 | 16.26% | ₩287.10 Billion ≈ $194.57 Million |
₩1.77 Trillion ≈ $1.20 Billion |
-11.63pp |
| 2004-12-31 | 27.89% | ₩452.30 Billion ≈ $306.52 Million |
₩1.62 Trillion ≈ $1.10 Billion |
+7.50pp |
| 2003-12-31 | 20.39% | ₩326.99 Billion ≈ $221.59 Million |
₩1.60 Trillion ≈ $1.09 Billion |
+9.02pp |
| 2002-12-31 | 11.37% | ₩46.21 Billion ≈ $31.32 Million |
₩406.36 Billion ≈ $275.38 Million |
+4.63pp |
| 2001-12-31 | 6.74% | ₩33.12 Billion ≈ $22.44 Million |
₩491.42 Billion ≈ $333.03 Million |
-3.18pp |
| 2000-12-31 | 9.92% | ₩42.96 Billion ≈ $29.11 Million |
₩432.99 Billion ≈ $293.43 Million |
-- |
About Green Cross
Green Cross Holdings Corporation operates as a biotechnology company. The company provides prescription drugs and over the counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pert… Read more